Skip to main content
. 2021 Oct 21;11(11):2792. doi: 10.3390/nano11112792

Table 2.

Effects of nanoparticles on the efficacy of immunotherapeutic treatment of hematological neoplasms.

Disease Target and Mechanism Compound Ref.
Acute myeloid leukemia Heme oxygenase 1 Lipid-polymer hybrid nanoparticle (hNP) is loaded with tin mesoporphyrin (SnMP) [84]
Inhibition of kinases Poly-lactide-co-glycolide core loaded with everolimus, albumin shell loaded with MAPK/STAT5 inhibitor, conjugated with monoclonal antibody against CD33 receptor. [89]
Proliferation of CD8+ T cells against AML cells Superparamagnetic iron-oxide nanoparticle core decorated with two humanized signaling proteins. HLA-A2-IgG4 hinge dimer molecules are conjugated to the core nanoparticle together with humanized anti-CD28 antibodies. [90]
Acute lymphoblastic leukemia Increased effect on CD19 cells (B leukemia cells)

  • Anti-CD19 antibody-conjugated, polyethylene glycol -biocompatibilized, and Nile Blue Raman reporter-tagged gold nanoparticles of urchin-like shape.

  • Doxorubicin encapsulated in polymeric nanoparticles with targeting ligands against CD19.

 [94]
[95]
Increased effect on CD3 cells (T leukemia cells)

  • Gelatin nanoparticles linked to NeutrAvidin and antibodies for the CD3 antigen.

  • Asparaginase containing poly (lactic-co-glycolic acid)

 [96]
[97]
Increased effect on CD 19 cells (T leukemia cells)

  • Gold-silver nanospheres conjugated with anti-CD19 monoclonal antibodies and marked with Nile-Blue-SERS-active molecules.

  • Sgc8c aptamer (Apt)-Dau-AuNPs complex.

 [101]


[102]
Lymphoma Increased production of cytokines (IFN γ, IL-2)

  • Silica-coated magnetic nanoparticles (MNPs@SiO2(RITC)) with conjugated ovalbumin.

 [112]
Increased antigen uptake Silica-coated magnetic nanoparticles (MNPs@SiO2 (RITC)) with conjugated ovalbumin [112]
Increased antigen-specific Th1 cell activity Silica-coated magnetic nanoparticles (MNPs@SiO2 (RITC)) with conjugated ovalbumin. [112]
Reduction of myeloid-derived suppressor cells Dox-loaded PEG-Fmoc-NLG micelles. [113]
Effect on Dendritic cells

  • Mannose (MN)-labeled poly (d, l-lactide-co-glycolide) nanoparticles encapsulating tumor-specific antigens.

 [114]
Increased production of cytokines(IL-7) OVA-bound nanoparticles encapsulating IL-7 [116]
Increased CD4+/CD8+ T cells Biotinylated CD20 and CD3 antibodies and ultra-small Fe3O4 nanoparticles with streptavidin and biotin. [118]
Action on cancer-associated fibroblasts scFv-Conjugated and ZnF16Pc-loaded ferritin nanoparticle [132]
Protracted drug/cell contact Rituxan conjugated to silver nanoparticles. [133]
Increased capping of CD20 Rituxan conjugated to silver nanoparticles. [133]
Multiple Myeloma Augment of specific memory CD0+ CTL response against MM cells Heteroclitic BCMA72-80 [YLMFLLRKI] peptide-encapsulated liposome or poly (lactic-co-glycolic acid) nanoparticles. [147]
Effect on cytokine production Heteroclitic BCMA72-80 [YLMFLLRKI] peptide-encapsulated liposome or poly (lactic-co-glycolic acid) nanoparticles. [147]
Blocking of tumor antigen escape Nanoparticle-based bispecific T-cell engagers (nanoBiTEs), decorated with anti-CD3 monoclonal antibodies (mAbs) targeting T cells, and mAbs targeting the cancer antigen. [148]